Cultural Adaptation of Drug Treatment for DJJ Youth (CAST)

July 9, 2026 updated by: University of California, San Francisco

The Cultural Adaptation of an Alcohol and Other Drug Use Treatment for Black Justice Involved Youth

This project aims to improve the understanding of the impact of Ethnic and Racial Discrimination (ERD) on adolescent alcohol and other drug use (AOD) within the Black Justice-Involved Youth (JIY) population. Individual interviews with Black JIY and focus groups with parents and guardians of Black JIY and community members who support change and reform in the justice community for Black JIY will be conducted.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Black JIY are overrepresented in the criminal justice system due to institutional racism and discrimination. The General Strain Theory posits that high levels of ethnic and racial discrimination (ERD), paired with elevated levels of witnessing or experiencing police brutality, places Black JIY at unique risk of increased alcohol and other drug use (AOD) as a means of coping with stressful events. Black JIY report engaging in comorbid alcohol and cannabis use to achieve temporary respite from discrimination-induced stress. While JIY engage in higher rates of comorbid alcohol and cannabis use compared to non-justice-involved youth, overall, Black JIY are less likely to be diverted to substance use treatment programs, less likely to engage in care after being released on probation, less likely to benefit from substance use treatment in terms of reduced risk of recidivism, and are more adversely affected by early onset of AOD activity than White JIY. To date, no known adolescent substance use treatment directly addresses ERD, the increased risk of AOD due to ERD, or explicitly presents tools on how to appropriately respond to AOD and discrimination distress among Black JIY. To address this problem, the investigator's research program aspires to improve the understanding of the impact of ERD on adolescent AOD within the Black JIY population. Individual interviews with Black JIY and focus groups with guardians of Black JIY and community members will be conducted. Data will be used to culturally adapt an adolescent substance use intervention. The culturally adapted intervention will then be piloted with 30 Black JIY.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
55

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94110
        • Recruiting
        • University of California, San Francisco
        • Contact:
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Completed
        • Medical University of South Carolina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

For Focus Groups and Interviews:

Black JIY Participants:

Inclusion Criteria:

• 1) Between the ages of 13-17; 2) identify as Black or African American; and 3) on community probation.

Exclusion Criteria:

• Will be excluded if they do not have parental consent to participate.

For Focus Groups and Interviews:

Adult Participants

Inclusion Criteria:

  • A guardian of JIY
  • An advocate (someone who supports change and reform in the justice community) for Black JIY.

Exclusion Criteria:

• Will be excluded if they do not provide consent to participate.

For pilot feasibility study:

Black JIY Participants:

Inclusion Criteria:

  • Between the ages of 13 and 17
  • Identify as Black or African American
  • Be on community probation
  • Meet criteria for alcohol, cannabis, or other drug misuse as defined by the DSM 5
  • Be experiencing at least 1 problem related to AOD;
  • The frequency of AOD must be weekly use over a 3-month period

Exclusion Criteria:

  • Will be excluded if they do not have parental consent to participate
  • Parole violation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: ADAP-ITT Phase 8
Phase 8 consists of piloting the culturally adapted CYT intervention with 30 Black JIY to examine feasibility and acceptability.
Behavioral: Culturally Adapted Adolescent Substance Use Treatment
The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
Other Names:
  • Cannabis Youth Treatment Series

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Feasibility and Acceptability
Time Frame: After study completion, an average of 3 months
Participants will complete feasibility and acceptability questionnaires and provide qualitative data on likes and dislikes about the intervention, delivery, session structure, and content.
After study completion, an average of 3 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in substance use
Time Frame: Baseline, after each study visit, at study completion, up to 3 months post-intervention, an average of 6 months.
Participants will complete urinalysis
Baseline, after each study visit, at study completion, up to 3 months post-intervention, an average of 6 months.
Change in discrimination distress
Time Frame: baseline, after study completion, and up to 3 months post-intervention, an average of 6 months.
Participants will complete a discrimination distress assessment measure
baseline, after study completion, and up to 3 months post-intervention, an average of 6 months.
Change in mental health symptoms
Time Frame: Baseline, after each study visit, at study completion, up to 3 months post-intervention, an average of 6 months.
Participants will complete measures and questionnaires to monitor anxiety, depression, and trauma symptoms
Baseline, after each study visit, at study completion, up to 3 months post-intervention, an average of 6 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of California, San Francisco

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute on Drug Abuse (NIDA)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Brittany Bryant, DSW, University of California, San Francisco

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 15, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 30, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 18, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 17, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 22, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 13, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 23-40126
  • K23DA057412 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The datasets generated and/or analyzed during the current study are not publicly available since data is still being collected. De-identified data will be available upon reasonable request after the study is completed, and results have been reported to the public.

IPD Sharing Time Frame

IPD will be available after the study is completed and remain available upon reasonable request up to 1 year after the completion of the study.

IPD Sharing Access Criteria

To access IPD, requesters will need to submit a data analysis plan and formal proposal that describes planned analyses must be submitted. Once the PI approves the proposal, the PI and requester will sign a data agreement.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings